Data as of 3:16pm ET
| +0.015 / +0.59%|
The 6 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 4.75, with a high estimate of 6.50 and a low estimate of 4.00. The median estimate represents a +85.02% increase from the last price of 2.57.
The current consensus among 6 polled investment analysts is to Buy stock in CTi Biopharma Corp. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.